UPM Pharmaceuticals
UPM Pharmaceuticals, also known as UPM, is a leading contract development and manufacturing organisation (CDMO) headquartered in the United States. Founded in 2002, UPM has established itself as a key player in the pharmaceutical industry, specialising in the development and production of complex oral solid dosage forms. With operational facilities strategically located across the US, UPM is well-positioned to serve a diverse clientele, including both emerging biotech firms and established pharmaceutical companies. The company is renowned for its innovative approach to formulation development and its commitment to quality, which has earned it a strong reputation in the market. UPM's core services encompass formulation development, analytical testing, and commercial manufacturing, all tailored to meet the unique needs of its partners. With a focus on efficiency and regulatory compliance, UPM Pharmaceuticals continues to achieve significant milestones, solidifying its position as a trusted partner in the pharmaceutical landscape.
DitchCarbon Score
How does UPM Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
UPM Pharmaceuticals's score of 3 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
UPM Pharmaceuticals's reported carbon emissions
UPM Pharmaceuticals, headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without concrete figures, it is challenging to assess their carbon footprint or climate commitments. However, the company may still be engaged in industry-standard practices aimed at reducing environmental impact, although specific initiatives or pledges have not been disclosed. As the pharmaceutical industry increasingly focuses on sustainability, UPM Pharmaceuticals may be expected to align with broader climate goals in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
UPM Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
